日本慢性肾脏病患者中法布雷病筛查研究
本研究在日本2122例男性CKD患者中筛查法布雷病,包括1703例CKD 5D期和419例CKD 1-5期患者。结果显示CKD 5D期和CKD 1-5期的法布雷病患病率分别为0.06%(1/1703)和0.48%(2/419)。在CKD 1-5期患者中,血清α-半乳糖苷酶A活性与年龄呈负相关(P < 0.0001),与估算肾小球滤过率呈正相关(P < 0.0001)。
要点
- 男性CKD 1-5期患者法布雷病患病率(0.48%)高于CKD 5D期(0.06%)。
- 在CKD 1-5期患者中,血清α-Gal A活性随年龄增长而降低,随eGFR升高而升高。
- 对CKD 1-5期患者进行法布雷病筛查可能改善患者生存并减少CKD 5D期患者数量。
核心结论
- 男性CKD 1-5期患者的法布雷病患病率远高于CKD 5D期患者。
- 在CKD 1-5期患者中筛查法布雷病可能改善患者生存并减少CKD 5D期患者数量。
研究设计与样本
- 研究采用血清α-半乳糖苷酶A活性分析和GLA基因直接测序,对2122例男性CKD患者进行法布雷病筛查。
- 纳入患者包括1703例CKD 5D期和419例CKD 1-5期患者。
- 研究评估了CKD 1-5期患者中血清α-Gal A活性与混杂因素的相关性。
主要发现
- CKD 5D期患者法布雷病患病率为0.06%(1/1703),CKD 1-5期患者为0.48%(2/419)。
- 一例CKD 5D期患者携带新发GLA突变p.Met208Arg,两例CKD 1-5期患者分别携带c.370delG和p.Met296Ile突变。
- p.Met208Arg导致分子表面区域中度结构改变,但未影响α-Gal A的催化残基Asp170和Asp231。
- CKD 1-5期患者血清α-Gal A活性与年龄呈负相关(P < 0.0001),与估算肾小球滤过率呈正相关(P < 0.0001)。
临床怎么用
- 对于男性CKD 1-5期患者,可考虑进行法布雷病筛查以早期发现并干预。
- 筛查方法包括血清α-Gal A活性分析和GLA基因测序。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fabry disease (FD), an X-linked lysosomal storage disorder caused by a deficiency in alfa-galactosidase A (α-Gal A) activity due to mutations in the GLA gene, has a prevalence of 0-1.69% in patients undergoing haemodialysis; however, its prevalence in patients with chronic kidney disease (CKD) Stages 1-5 is unknown. METHODS: Serum α-Gal A activity analysis and direct sequencing of GLA were used to screen for FD in 2122 male patients with CKD, including 1703 patients with CKD Stage 5D and 419 with CKD Stages 1-5. The correlation between serum α-Gal A activity and confounding factors in patients with CKD Stages 1-5 was evaluated. RESULTS: FD prevalence rates in patients with CKD Stage 5D and CKD Stages 1-5 were 0.06% (1/1703) and 0.48% (2/419), respectively. A patient with CKD Stage 5D exhibited a novel GLA mutation, p.Met208Arg, whereas two patients with CKD Stages 1-5 had c.370delG and p.Met296Ile. p. Met208Arg caused moderate structural changes in the molecular surface region near the substituted amino acid residue but did not affect the catalytic residues Asp170 and Asp231 in α-Gal A. Serum α-Gal A activity in patients with CKD Stages 1-5 was inversely correlated with age (P < 0.0001) but directly correlated with estimated glomerular filtration rate (P < 0.0001). CONCLUSIONS: FD prevalence was much higher in male patients with CKD Stages 1-5 than in those with CKD Stage 5D. FD screening in patients with CKD Stages 1-5 may improve patient survival, decreasing the number of patients with CKD Stage 5D.
引用
- Nagata A, Nasu M, Kaida Y, et al. Screening of Fabry disease in patients with chronic kidney disease in Japan. Nephrol Dial Transplant. 2021. PMID: 34282462. doi:10.1093/ndt/gfaa324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。